Two decades after the first HPV vaccines reached market, the global landscape of women's cancer prevention has fundamentally shifted. What began as a focused intervention against a sexually transmitted virus has evolved into one of the most significant cancer prevention tools in modern medicine, positioning women's health at the forefront of international disease control strategies. The human papillomavirus vaccination programs have demonstrated measurable reductions in cervical precancers and invasive cervical cancers across multiple populations. Real-world data from countries with robust vaccination programs show substantial declines in high-grade cervical lesions among vaccinated cohorts, with some regions reporting reductions exceeding 80% in targeted age groups. Beyond cervical cancer, emerging evidence suggests protective effects against other HPV-related malignancies, including vulvar, vaginal, and oropharyngeal cancers. However, this progress illuminates stark global inequities in access and implementation. While high-income nations achieve vaccination coverage rates above 70%, many low- and middle-income countries—where cervical cancer burden remains highest—struggle with supply chains, healthcare infrastructure, and vaccine hesitancy. The challenge ahead extends beyond vaccine delivery to comprehensive screening integration and addressing the estimated 600,000 annual cervical cancer cases that still occur globally. From a longevity perspective, these vaccination programs represent a paradigm shift toward proactive cancer prevention rather than reactive treatment. The data suggests that sustained, equitable HPV vaccination could eliminate cervical cancer as a public health threat within decades, fundamentally altering cancer mortality patterns for future generations of women worldwide.